Navigation Links
Transcept Pharmaceuticals to Present at Rodman & Renshaw and Stifel Nicolaus Investor Conferences in September 2010
Date:9/7/2010

Transcept Pharmaceuticals to Present at Rodman & Renshaw and Stifel Nicolaus Investor... -- POINT RICHMOND, Calif., Sept. 7 /PRNewswire-FirstCall/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Banking & Financial Services, Health Care & Hospitals, Pharmaceuticals, Trade Show News Click to view news release full screen  

Transcept Pharmaceuticals to Present at Rodman & Renshaw and Stifel Nicolaus Investor Conferences in September 2010

 

POINT RICHMOND, Calif., Sept. 7 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc.  (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced that Transcept management is scheduled to participate in these upcoming investor conferences:Rodman and Renshaw Annual Global Investment ConferenceNew York, NYSeptember 14, 2010 at 5:20 p.m. EDTA live audio webcast and replay of this presentation may be accessed at http://www.wsw.com/webcast/rrshq18/tspt and on the Transcept Investor webpage at www.transcept.com.Stifel Nicolaus Healthcare ConferenceBoston, MASeptember 16, 2010 at 9:10 a.m. EDTA live audio webcast and replay of this presentation may be accessed at http://www.veracast.com/webcasts/stifel/healthcare2010/65203465.cfm and on the Transcept Investor webpage at www.transcept.com.About TransceptTranscept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. The most advanced Transcept product candidate is Intermezzo® (zolpidem tartrate sublingual tablet), for which a New Drug Application (NDA) was submitted to the U.S. Food and Drug Administration (FDA) in September 2008 seeking approval as a prescription sleep aid for use in the middle of the night at the time a patient awakens and has difficulty returning to sleep. In October 2009, Transcept received a Complete Response Letter from the FDA on the Intermezzo® NDA and is working to respond to issues raised in the letter. Transcept and Purdue Pharmaceutical Products L.P. have entered into a collaboration agreement for the development and commercialization of Intermezzo® in the United States.  Transcept is also developing TO-2061, an ultra low dose ondansetron augmentation therapy for patients with obsessive compulsive disorder (OCD) who have not adequately responded to treatment with SSRIs.  Transcept plans to begin a Phase 2 study of TO-2061 in 2011.  For further information, please visit the Transcept website at: www.transcept.com.

Contact:Transcept Pharmaceuticals, Inc.Greg MannDirector, Corporate Communications(510) 215-3567gmann@transcept.com
'/>"/>

SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Transcept Pharmaceuticals Receives Notice of Allowance for Second U.S. Patent Application Covering Intermezzo(R)
2. Transcept Pharmaceuticals Scheduled to Meet With FDA to Discuss Intermezzo(R) Complete Response Letter
3. Transcept Pharmaceuticals Reports Third Quarter 2009 Financial Results
4. Transcept Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference on November 17
5. Transcept Pharmaceuticals to Report Third Quarter 2009 Results and Host Conference Call on November 12
6. Transcept Pharmaceuticals Receives Complete Response Letter from FDA on Intermezzo(R) New Drug Application
7. Transcept Pharmaceuticals to Report First Quarter 2009 Results
8. Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings
9. Transcept Pharmaceuticals Announces Intent to Submit New Drug Application for Intermezzo(R) in Third Quarter 2008
10. Cadence Pharmaceuticals to Present at Four Investment Conferences During the Month of September 2010
11. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... LONDON , Jan. 19, 2017 ... 2022 Summary GlobalData,s new report, "Germany Cataract ... data on the Germany Cataract Surgery Devices market. The ... (in units) and average prices (USD) within market segements ... The report also provides company shares and distribution shares ...
(Date:1/19/2017)... 2017 The global immunomodulators market is ... according to a new study by Grand View ... predominantly driven by high R&D investments employed by ... of new and therapeutically advanced drugs. This is ... an unprecedented rate into the immunomodulators market hence ...
(Date:1/19/2017)... , Jan. 19, 2017 Report Details ... Market? Which areas are going to grow at the ... to 2026, assessing data, trends, opportunities and prospects. ... Discover the most lucrative areas in the industry and ... assess forecasted sales across the all the major categories ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... January 19, 2017 , ... WholeHealth is announcing their participation ... Paziotopoulos, Andrew Petersen and Trish Henrie-Barrus will be present Saturday and Sunday in ... program. , “We know it’s easy to get carried away when you’re ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... CTMS, which provides a modern CTMS workflow designed to seamlessly integrate and streamline ... been condensed to a single page, maximizing usability and improving efficiency significantly for ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... panel system. , The Tranquility privacy panel system was designed to deliver ... Tranquility panels help reduce noise and provide the visual privacy required to maintain ...
(Date:1/19/2017)... ... January 19, 2017 , ... Rountree Brady ... services to communities throughout eastern Georgia, is embarking on a charity effort to ... disease kills more Americans every year than anything else, yet risk factors associated ...
(Date:1/19/2017)... , ... January 19, 2017 , ... Attorney Robert ... fifth consecutive year donated money to the Triumph Over Kid Cancer foundation. Each year, ... one of those children. James saw firsthand the effect of the critical funding gap ...
Breaking Medicine News(10 mins):